ProCE Banner Activity

TROPION-Lung02: Initial Results From Phase I Study of Datopotamab Deruxtecan + Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC

Slideset Download
Conference Coverage
In patients with metastatic NSCLC and no actionable mutations, Dato-DXd plus pembrolizumab ± platinum chemotherapy was associated with a tolerable safety profile and promising response rate.

Released: August 18, 2022

Expiration: August 17, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc